J P Kitzmann1, D O'Gorman2, T Kin2, A C Gruessner1, P Senior2, S Imes2, R W Gruessner1, A M J Shapiro2, K K Papas3. 1. Department of Surgery, University of Arizona, Tucson, AZ. 2. Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada. 3. Department of Surgery, University of Arizona, Tucson, AZ. Electronic address: kkpapas@surgery.arizona.edu.
Abstract
BACKGROUND: Human islet allotransplantation for the treatment of type 1 diabetes is in phase III clinical trials in the U.S. and is the standard of care in several other countries. Current islet product release criteria include viability based on cell membrane integrity stains, glucose-stimulated insulin release, and islet equivalent (IE) dose based on counts. However, only a fraction of patients transplanted with islets that meet or exceed these release criteria become insulin independent following 1 transplant. Measurements of islet oxygen consumption rate (OCR) have been reported as highly predictive of transplant outcome in many models. METHOD: In this article we report on the assessment of clinical islet allograft preparations using OCR dose (or viable IE dose) and current product release assays in a series of 13 first transplant recipients. The predictive capability of each assay was examined and successful graft function was defined as 100% insulin independence within 45 days post-transplant. RESULTS: OCR dose was most predictive of CTO. IE dose was also highly predictive, while glucoses stimulated insulin release and membrane integrity stains were not. CONCLUSION: OCR dose can predict CTO with high specificity and sensitivity and is a useful tool for evaluating islet preparations prior to clinical human islet allotransplantation.
BACKGROUND:Human islet allotransplantation for the treatment of type 1 diabetes is in phase III clinical trials in the U.S. and is the standard of care in several other countries. Current islet product release criteria include viability based on cell membrane integrity stains, glucose-stimulated insulin release, and islet equivalent (IE) dose based on counts. However, only a fraction of patients transplanted with islets that meet or exceed these release criteria become insulin independent following 1 transplant. Measurements of islet oxygen consumption rate (OCR) have been reported as highly predictive of transplant outcome in many models. METHOD: In this article we report on the assessment of clinical islet allograft preparations using OCR dose (or viable IE dose) and current product release assays in a series of 13 first transplant recipients. The predictive capability of each assay was examined and successful graft function was defined as 100% insulin independence within 45 days post-transplant. RESULTS:OCR dose was most predictive of CTO. IE dose was also highly predictive, while glucoses stimulated insulin release and membrane integrity stains were not. CONCLUSION:OCR dose can predict CTO with high specificity and sensitivity and is a useful tool for evaluating islet preparations prior to clinical human islet allotransplantation.
Authors: Andrew M Posselt; Gregory L Szot; Lynda A Frassetto; Umesh Masharani; Mehdi Tavakol; Raj Amin; Joan McElroy; Marissa D Ramos; Robert K Kerlan; Lawrence Fong; Flavio Vincenti; Jeffrey A Bluestone; Peter G Stock Journal: Transplantation Date: 2010-12-27 Impact factor: 4.939
Authors: Klearchos K Papas; Clark K Colton; Andi Qipo; Haiyan Wu; Rebecca A Nelson; Bernhard J Hering; Gordon C Weir; Maria Koulmanda Journal: J Invest Surg Date: 2010-02 Impact factor: 2.533
Authors: N A Turgeon; J G Avila; J A Cano; J J Hutchinson; I R Badell; A J Page; A B Adams; M H Sears; P H Bowen; A D Kirk; T C Pearson; C P Larsen Journal: Am J Transplant Date: 2010-09 Impact factor: 8.086
Authors: A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: M D Bellin; F B Barton; A Heitman; J V Harmon; R Kandaswamy; A N Balamurugan; D E R Sutherland; R Alejandro; B J Hering Journal: Am J Transplant Date: 2012-04-11 Impact factor: 8.086
Authors: David E R Sutherland; Angelika C Gruessner; Annelisa M Carlson; Juan J Blondet; A N Balamurugan; Katie F Reigstad; Gregory J Beilman; Melena D Bellin; Bernhard J Hering Journal: Transplantation Date: 2008-12-27 Impact factor: 4.939
Authors: Franca B Barton; Michael R Rickels; Rodolfo Alejandro; Bernhard J Hering; Stephen Wease; Bashoo Naziruddin; Jose Oberholzer; Jon S Odorico; Marc R Garfinkel; Marlon Levy; Francois Pattou; Thierry Berney; Antonio Secchi; Shari Messinger; Peter A Senior; Paola Maffi; Andrew Posselt; Peter G Stock; Dixon B Kaufman; Xunrong Luo; Fouad Kandeel; Enrico Cagliero; Nicole A Turgeon; Piotr Witkowski; Ali Naji; Philip J O'Connell; Carla Greenbaum; Yogish C Kudva; Kenneth L Brayman; Meredith J Aull; Christian Larsen; Tom W H Kay; Luis A Fernandez; Marie-Christine Vantyghem; Melena Bellin; A M James Shapiro Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112
Authors: Amy C Kelly; Kate E Smith; William G Purvis; Catherine G Min; Craig S Weber; Amanda M Cooksey; Craig Hasilo; Steven Paraskevas; Thomas M Suszynski; Bradley P Weegman; Miranda J Anderson; Leticia E Camacho; Robert C Harland; Thomas Loudovaris; Jana Jandova; Diana S Molano; Nicholas D Price; Ivan G Georgiev; William E Scott; Derek M D Manas; James A M Shaw; Doug OʼGorman; Tatsuya Kin; Fiona M McCarthy; Gregory L Szot; Andrew M Posselt; Peter G Stock; Theodore Karatzas; A M James Shapiro; Ronald M Lynch; Sean W Limesand; Klearchos K Papas Journal: Transplantation Date: 2019-01 Impact factor: 4.939
Authors: Nathaniel J Hart; Craig Weber; Nicholas Price; Alma Banuelos; Madison Schultz; Barry Huey; Emily Harnois; Cyonna Gibson; Leah V Steyn; Klearchos K Papas; Ronald M Lynch Journal: Am J Physiol Cell Physiol Date: 2021-06-09 Impact factor: 5.282
Authors: Bradley P Weegman; Venkata Sunil Kumar Sajja; Thomas M Suszynski; Michael D Rizzari; William E Scott Iii; Jennifer P Kitzmann; Kate R Mueller; Thomas R Hanley; David J Kennedy; Paul W Todd; Appakalai N Balamurugan; Bernhard J Hering; Klearchos K Papas Journal: J Diabetes Res Date: 2016-10-23 Impact factor: 4.011
Authors: Klearchos K Papas; Melena D Bellin; David E R Sutherland; Thomas M Suszynski; Jennifer P Kitzmann; Efstathios S Avgoustiniatos; Angelika C Gruessner; Kathryn R Mueller; Gregory J Beilman; Appakalai N Balamurugan; Gopalakrishnan Loganathan; Clark K Colton; Maria Koulmanda; Gordon C Weir; Josh J Wilhelm; Dajun Qian; Joyce C Niland; Bernhard J Hering Journal: PLoS One Date: 2015-08-10 Impact factor: 3.240
Authors: Darling M Rojas-Canales; Michaela Waibel; Aurelien Forget; Daniella Penko; Jodie Nitschke; Fran J Harding; Bahman Delalat; Anton Blencowe; Thomas Loudovaris; Shane T Grey; Helen E Thomas; Thomas W H Kay; Chris J Drogemuller; Nicolas H Voelcker; Patrick T Coates Journal: Endocr Connect Date: 2018-02-26 Impact factor: 3.335